Zhuhai Trinomab Pharmaceutical Co., Ltd. is an innovative biopharmaceutical company with a global expansion perspective that integrates research and development, production and sales. The core technology of the company is known as the fourth-generation antibody technology HitmAb?, a proprietary technology platform featuring differentiated advantages and high efficiency for the discovery of fully native human mAbs against infectious diseases, autoimmune disorders, malignant tumors and other human diseases.
Harnessing the power of HitmAb?, Trinomab is developing a robust product pipeline of fully native human mAbs as candidates for more than 20 different application targets including both foreign antigens such as toxins and viruses and host molecules such as NGF. A number of our lead products are focused on replacing plasma-derived immunoglobulins currently in used against infectious pathogens such as tetanus toxin, rabies virus and cytomegalovirus while some are focused on promoting more effective or neglected therapeutics for children against diseases such as respiratory syncytial virus (RSV) and Varicella-Zoster virus. TNM002 injection，an innovative monoclonal antibody formulation independently developed by the company, is the world's first recombinant anti-tetanus toxin monoclonal antibody for prophylaxis against tetanus. TNM002 has been granted the “Breakthrough” designation from the China NMPA in March 2022, and “Fast-track designation from USA FDA in August of the same year. New Drug Application (NDA) for TNM002 has been formally accepted by China NMPA in December 2023 and has then been awarded with the priority review process by the administration.
Upholding the mission of “create clinical value”, Trinomab has been focused on the R&D and industrialization of fully native human mAbs with the goal to develop novel therapeutics that are safe, efficient and accessible to meet clinical needs and benefits for patients across the globe.
